WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Exit Postmarket & security

THE TAPE

Boston Scientific says plants and shipping are fully back 17 days after the cyberattack FDA only partly recognizes the 2025 biocompatibility standard and skips clause 6.9 ARPA-H commits $62.7M to autonomous heart failure AI and wants FDA packages in two years Stryker puts the March cyberattack at about $45M of Q3 sales Glucotrack raises $11.5M in convertible notes at a 22 percent original issue discount Cardiovascular AI notification software gets its own Class II regulation and a 510(k) path CMS covers TAVR for asymptomatic patients and drops the evidence requirement for symptomatic ones Nvidia takes its first equity stake in Verily Bausch + Lomb wins a CE mark for the SeeLyra femtosecond laser Boston Scientific says plants and shipping are fully back 17 days after the cyberattack FDA only partly recognizes the 2025 biocompatibility standard and skips clause 6.9 ARPA-H commits $62.7M to autonomous heart failure AI and wants FDA packages in two years Stryker puts the March cyberattack at about $45M of Q3 sales Glucotrack raises $11.5M in convertible notes at a 22 percent original issue discount Cardiovascular AI notification software gets its own Class II regulation and a 510(k) path CMS covers TAVR for asymptomatic patients and drops the evidence requirement for symptomatic ones Nvidia takes its first equity stake in Verily Bausch + Lomb wins a CE mark for the SeeLyra femtosecond laser

Talks

GE HealthCare is in talks to buy Sofie Biosciences for about $1B

MedDevice Startups Staff · 1 day ago · 2 min read · Via Fierce Biotech

GE HealthCare is in advanced talks to buy Sofie Biosciences for about $1 billion, the Financial Times reported on September 13. The report cites people familiar with the matter and says a deal could land as soon as this week. Neither company has commented.

Sofie makes PET radiopharmaceuticals and the imaging chemicals used to find cancer on scans. The Virginia company has been operating for roughly 20 years. GE HealthCare consolidated its imaging business units earlier this year.

Nothing here is signed. Treat the price as a reported figure until one of the two issues a release or makes a filing. The direction is the useful part for a startup. GE HealthCare is shopping for the chemistry that feeds the scanner rather than for another scanner.

Questions & Answers

Is GE HealthCare acquiring Sofie Biosciences?

The Financial Times reported on September 13, 2026 that GE HealthCare is in advanced talks to buy Sofie Biosciences for about $1 billion. Neither GE HealthCare nor Sofie Biosciences has confirmed the report.

What does Sofie Biosciences make?

Sofie Biosciences is a Virginia based company that produces PET radiopharmaceuticals and the imaging chemicals used to detect cancer on scans. It has been operating for roughly 20 years.

How much is the reported GE HealthCare deal for Sofie Biosciences worth?

Reports put the price at about $1 billion. The figure comes from Financial Times sources familiar with the talks, and neither company has confirmed it.

← Back to M&A